UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog

By
A A A

Innovator companies, which have spent millions on the development of branded drugs, often face patent challenges from companies looking to bring in generic versions of the drug prior to the loss of patent exclusivity. In such a scenario, the innovator companies usually file a patent infringement lawsuit against the generic company to delay the entry of generic versions.

A similar step was taken late last week by UCB ( UCBJF ) which is facing a patent challenge from Actavis ( ACT ) for Neupro. Actavis has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking marketing approval for its generic version of UCB's Neupro (1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr).

UCB filed a lawsuit against Actavis in the U.S. District Court for the District of Delaware in order to prevent Actavis from commercializing its generic version of Neupro prior to the expiration of certain U.S. patents.

Neupro is approved for the treatment of signs and symptoms of idiopathic Parkinson's disease and moderate-to-severe primary restless legs syndrome (RLS).

With the lawsuit being filed under the provisions of the Hatch-Waxman Act, the FDA cannot grant final approval to Actavis' generic version for up to 30 months from the date the notice was received notice by UCB about the ANDA filing or until final resolution of the matter before the court, whichever occurs sooner.

Actavis believes it is "first to file" an ANDA for a generic version of Neupro and might be entitled to 180 days of generic market exclusivity if the FDA approves the ANDA.

As per IMS Health data, Neupro generated sales of $85 million in the last 12 months, ending Jun 30, 2014, in the U.S.

UCB and Actavis carry a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Mallinckrodt plc ( MNK ) and Akorn, Inc. ( AKRX ). Both sport a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UCB SA (UCBJF): Get Free Report

ACTAVIS PLC (ACT): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: RLS , UCBJF , ACT , MNK , AKRX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

47,194,318
  • $100.29 ▼ 1.32%
44,972,035
    $16.74 unch
41,565,092
  • $42.49 ▼ 0.14%
39,543,541
  • $13.72 ▲ 29.56%
39,250,175
  • $17.67 ▲ 6.83%
26,903,652
  • $75.874 ▲ 1.74%
23,600,178
  • $99.341 ▲ 0.83%
23,398,379
  • $6.74 ▼ 2.88%
As of 9/16/2014, 01:50 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com